Integrated BioPharma heads into the week with a share price of $0.265 and an ownership structure so concentrated that conventional short-side pressure is almost irrelevant.
The ownership picture is the defining feature here. Damon DeSantis holds 41.6% of the company outright, a position reported as recently as April 15. The DeSantis family and affiliated estates collectively account for well over half of all shares on issue. With that degree of insider concentration, the free float is thin and trading activity is inherently constrained. That context matters for every other data point in this note.
Short interest tells a quiet story. Estimated shorts amount to roughly 0.03% of the free float — a negligible level by any standard. The most recent official FINRA fortnightly figure puts shares short at just 2,101, with days-to-cover at 1.0. The short-interest and cost-to-borrow data are both stale by more than six weeks, so the precise numbers carry limited weight. What the utilisation data does confirm is that availability is fully open — utilisation has read 0% every day since mid-March, after a brief 19.7% reading on March 18. There is no lending pressure here, no squeeze risk, and no signal from the borrow market worth trading on.
The stock itself edged up 0.76% on the week to close at $0.265, recovering slightly from a 10% slide over the prior month. There are no analyst ratings, no options activity, and no meaningful valuation multiples available for a name of this size and OTC status. The enterprise value is estimated at roughly $8.8 million, consistent with a micro-cap operating in personal care products. Given the thin float and the absence of institutional coverage, price moves here tend to reflect news flow and retail sentiment rather than fundamental re-rating.
The earnings calendar is worth noting. The next scheduled event is May 12. The historical pattern is not encouraging — all four prior earnings dates in the available record produced negative next-day returns, ranging from -0.8% to -6.1%. The five-day reactions were more mixed, with two negative and two positive outcomes. That pattern reflects the unpredictability typical of thinly traded micro-caps around reporting dates rather than any systematic directional bias.
With the next earnings print less than two weeks away, the question for anyone watching INBP is whether May 12 brings any update on operations or capital structure that could shift the narrative in a name where concentrated ownership, thin liquidity, and a near-zero short position leave the price almost entirely at the mercy of news.
See the live data behind this article on ORTEX.
Open INBP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
